McKesson posted double-digit fiscal 2026 growth, led by oncology, multispecialty, and prescription technology services. The stock earns a Buy, but valuation and a leveraged balance sheet keep the upside more measured.
McKesson (MCK) earns a Buy rating for moderate-risk investors with a medium-term horizon. The investment case rests on a scaled pharmaceutical distribution franchise, faster growth in oncology and multispecialty services, technology-enabled prescription access, and consistent capital returns.
Fiscal 2026 revenue rose 12% to $403.4B, operating profit increased 15% to $6.5B, and adjusted EPS grew 18% to $39.11. Management entered fiscal 2027 with adjusted EPS guidance of $43.80 to $44.60, representing 12% to 14% growth, while reaffirming a long-term adjusted EPS growth target of 13% to 16%.
The growth engine is shifting toward higher-value platforms. Oncology and Multispecialty revenue increased 31% in fiscal 2026, with operating profit up 53%, while Prescription Technology Solutions operating profit rose 17%. North American Pharmaceutical remains the cash-generating core, producing $336.7B of fiscal 2026 revenue and $3.5B of adjusted segment operating profit.
The main restraint is valuation and financial structure. At a current price of $846.11, MCK trades at 21.6x trailing earnings and 19.3x forward earnings, while its annual balance-sheet series shows $6.8B of debt, $4.0B of cash, a 0.85 current ratio, and negative equity of $2.2B. Strong free cash flow reduces the balance-sheet pressure, but it does not eliminate it.
Founded in 1833 and headquartered in Irving, Texas, McKesson is a healthcare distribution and services company with 41,600 employees. The company distributes branded, generic, specialty, biosimilar, and over-the-counter medicines, while also providing logistics, technology, oncology, pharmacy, and patient-access services.
McKesson's business model is built on high volume and low consolidated margins. Fiscal 2026 revenue reached $403.4B, while gross margin was 3.6%, operating margin was 1.6%, and net margin was 1.2%. The economics depend on scale, inventory execution, service reliability, and the ability to add higher-margin services around the distribution network.
The company reports four operating segments: North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. North American Pharmaceutical represented 83.4% of fiscal 2026 revenue, Oncology and Multispecialty represented 12.0%, Medical-Surgical Solutions represented 2.9%, and Prescription Technology Solutions represented 1.4%.
McKesson completed its exit from Norway in January 2026 and is preparing Medical-Surgical Solutions for separation. The company expects to retain operating control and majority ownership after Apollo's planned $1.25B investment for an approximately 13% minority interest in the medical business.
North American Pharmaceutical is the foundation of MCK. Fiscal 2026 revenue increased 11% to $336.7B, and adjusted segment operating profit rose 10% to $3.5B. In the fourth quarter, revenue increased 3% to $79.1B and operating profit rose 11% to $980M, despite lower branded pharmaceutical contributions.
GLP-1 distribution revenue reached $53B in fiscal 2026, up 27%, including $14B in the fourth quarter. Fourth-quarter GLP-1 revenue increased 22% year over year but declined 4% sequentially. The sequential volume decline had no impact on segment operating profit, which shows that MCK's earnings depend more on service economics and mix than on revenue growth alone.
Oncology and Multispecialty is the strongest growth segment. Fiscal 2026 revenue increased 31% to $48.4B, while adjusted operating profit grew 53% to $1.4B. Fourth-quarter revenue rose 35% to $12.7B and operating profit increased 53% to $385M. Organic operating profit growth was 13% after excluding acquisition effects.
Prescription Technology Solutions produced $5.8B of fiscal 2026 revenue, up 11%, and $1.1B of adjusted operating profit, up 17%. The segment generated a 19.5% adjusted operating margin, far above the company's 3.6% consolidated gross margin. That margin profile gives this smaller segment an outsized role in mix improvement.
Medical-Surgical Solutions generated $11.5B of fiscal 2026 revenue, up 1%. Fourth-quarter revenue rose 1% to $2.9B, while operating profit declined 5% to $271M as vaccine and testing demand fell below the prior year. The planned separation may sharpen strategic focus, but the segment's recent growth profile is slower than Oncology and Multispecialty.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
MCK's flagship offering is its North American pharmaceutical distribution platform rather than a single medicine. The platform distributes approximately one-third of pharmaceuticals in North America and connects manufacturers, pharmacies, hospitals, clinics, and other care settings through a regulated logistics network.
The platform's most important current growth category is specialty medicine, including GLP-1 therapies. Fiscal 2026 GLP-1 distribution revenue of $53B and fourth-quarter revenue of $14B show the scale of this category within the core franchise. Specialty distribution also supports the Oncology and Multispecialty segment, where provider additions and acquisitions are expanding the addressable service base.
The product's strength is reliability rather than consumer visibility. North American Pharmaceutical delivered $3.5B of adjusted operating profit in fiscal 2026, and fourth-quarter operating profit grew 11% even as branded pricing reduced revenue growth by approximately 3 percentage points. That combination illustrates the value of scale, purchasing processes, inventory control, and distribution density.
MCK's competitive advantage combines scale, regulated infrastructure, workflow integration, and data. The company is digitally connected to more than 50,000 pharmacies, over 1 million providers, and more than 650 biopharma brands. Those connections create a platform for distribution, patient access, and manufacturer services.
The company's oncology platform illustrates that strategy. Ambient Scribe technology is used by more than 1,900 providers, while Ontada incorporates in-office dispensing data from Florida Cancer Specialists and Research Institute. The combination of provider workflow tools and clinical data gives MCK more ways to serve practices and biopharma customers.
MCK also launched an integrated specialty access and affordability solution that connects benefits verification, prior authorization, and affordability support in one workflow. During fiscal 2026, the broader platform supported 3.4 million patients, helped patients save approximately $10B on brand and specialty medicines, and helped prevent an estimated 12 million prescriptions from being abandoned because of affordability challenges.
The moat is operational and relational rather than brand-driven. A new entrant would need compliant distribution facilities, pharmacy and provider connectivity, manufacturer relationships, data systems, and dependable service performance. MCK's 34% fiscal 2026 return on invested capital and $5.1B of shareholder returns demonstrate that management has converted this infrastructure into financial output.
MCK's operating model depends on moving large quantities of medicines accurately and on schedule. The company opened a new Montreal distribution center with automated storage and retrieval systems powered by AI and robotics. The facility adds capacity and is designed to improve service reliability across Eastern Canada.
The company also implemented an AI-driven planning system that connects demand, supply, inventory, and operations. Management said the system contributed to working-capital savings and fiscal 2026 operating cash flow of $6.2B. The annual cash-flow statement records $436M of capital expenditures for the year.
Operational resilience was tested in January 2026 when winter weather affected transportation networks across more than 20 states. MCK reported that early risk monitoring and proactive planning maintained safe operations and minimized disruption to customers and patients.
The supply chain remains exposed to product shortages, manufacturer relationships, cybersecurity incidents, and regulatory requirements. MCK's 2026 10-K identifies supply disruption, information-system failures, and compliance obligations as material business risks. The company's scale helps absorb these pressures, but the same scale also makes execution failures financially consequential.
The healthcare distribution market is large and growing. Mordor Intelligence estimates the market at $1.11T in 2025 and $1.61T by 2031, implying a 6.4% compound annual growth rate. A separate 360iResearch estimate places the 2025 market at $1.37T, providing a higher reference point but the same broad conclusion about market scale.
Specialty distribution is the most attractive market pocket. Mordor estimates specialty distribution growth at 9.3%, ahead of the overall market, driven by oncology, immunology, and rare-disease therapies. Cold-chain logistics is also estimated to grow at 8.4% through 2031 as biologics and temperature-sensitive therapies expand.
The market structure favors established operators. Traditional full-line wholesalers held 33.0% of market revenue in 2025, while warehousing and storage represented 46.1%. MCK's one-third share of North American pharmaceutical distribution positions it to benefit from volume growth, but generic pricing pressure and direct manufacturer distribution limit how much of that volume becomes profit.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
MCK serves retail pharmacies, hospitals, long-term care centers, clinics, physician offices, surgery centers, laboratories, nursing homes, hospice providers, home-health agencies, government facilities, and online marketplaces. Its customer base also includes biopharma manufacturers that use distribution, data, access, and affordability services.
The network's scale is central to customer value. MCK supports more than 50,000 pharmacies and over 1 million providers, while its biopharma services platform covers more than 650 brands. In fiscal 2026, the platform enabled patients to access medicines more than 135 million times.
Customer needs differ by channel. Retail pharmacies prioritize dependable replenishment and affordability tools, community oncology practices need provider support and clinical workflow services, and biopharma companies need data and faster time to therapy. MCK's segment mix gives it exposure to all three demands, while its 2026 10-K identifies customer concentration, contract nonrenewals, payment defaults, and bankruptcies as risks.
Cencora (COR) and Cardinal Health (CAH) are MCK's primary national competitors in pharmaceutical distribution, wholesaling, and logistics. The broader competitive set includes regional distributors, specialty distributors, third-party logistics providers, self-warehousing chain pharmacies, manufacturers that distribute directly, and large payer organizations.
MCK's relative strength is the combination of national distribution scale and adjacent specialty services. Oncology and Multispecialty generated $1.4B of adjusted operating profit in fiscal 2026, while Prescription Technology Solutions generated $1.1B with a 19.5% adjusted operating margin. These businesses give MCK a higher-value layer beyond traditional wholesale volume.
Competition still limits pricing power. Generic drug pricing, manufacturer direct distribution, self-warehousing, and healthcare consolidation can pressure revenue and margins. MCK's 3.6% gross margin and 1.6% operating margin show why small changes in purchasing economics, service fees, or operating efficiency matter.
Healthcare policy is the most direct macro variable in MCK's results. The company navigated the first wave of branded pharmaceutical price changes related to the Inflation Reduction Act during fiscal 2026. Management said those changes reduced revenue growth, while North American Pharmaceutical operating profit still increased 10% for the year.
Reimbursement, payer utilization, formulary requirements, government funding, and drug-pricing policy influence MCK's customers and manufacturer relationships. Prescription Technology Solutions specifically cited payer utilization, formulary requirements, product delays, and program changes as causes of quarter-to-quarter variation.
Supply-chain disruption is another macro-sensitive risk. January 2026 winter weather strained transportation networks across more than 20 states, yet MCK reported that proactive planning minimized service interruption. That event supports the value of resilience investments, including the Montreal distribution center and AI-based inventory planning.
MCK completed its European exit through the January 2026 Norway divestiture, reducing direct exposure to European operations. The remaining strategic focus is North American distribution, specialty care, patient access, and technology services. Opioid litigation remains a material legal and cash-flow consideration, with fiscal 2026 opioid-related charges of $57M identified in the business context.
Debt of $6.8B, cash of $4.0B, a 0.85 current ratio, and negative equity of $2.2B leave McKesson's balance sheet stretched, even though strong free cash flow helps offset the pressure.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Revenue rose 12% to $403.4B in fiscal 2026 while operating profit climbed 15% and adjusted EPS advanced 18% to $39.11, showing solid operating leverage.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management guided fiscal 2027 adjusted EPS to $43.80-$44.60, implying 12% to 14% growth and staying in line with its long-term 13% to 16% target.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At $846.11, McKesson trades at 21.6x trailing earnings and 19.3x forward earnings, leaving valuation as a key constraint despite strong growth.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →With a current price of $846.11 and a fair value of $947.13, McKesson sits below the level that would justify a more aggressive stance.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →McKesson is a strong operator in a structurally difficult industry. Fiscal 2026 combined $403.4B of revenue, $6.5B of operating profit, $5.7B of free cash flow, and 18% adjusted EPS growth. The company also enters fiscal 2027 with clear segment guidance and a long-term earnings target of 13% to 16% growth.
The investment is not risk-free. Negative equity, a 0.85 current ratio, low distribution margins, opioid litigation, healthcare policy, cybersecurity, and direct-distribution threats all deserve attention. Those risks explain the moderate-risk framing and keep the recommendation at Buy rather than Strong Buy.
At $846.11, MCK offers exposure to a scaled healthcare network with improving specialty and technology economics. The combination of a $947.13 fair value estimate, recurring share repurchases, strong cash generation, and a seven-quarter EPS beat streak gives patient investors a credible path to long-term wealth building, provided the balance sheet and regulatory risks remain manageable.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
McKesson Corporation (MCK) rose after beating EPS and revenue estimates, but the real story goes beyond the headline. This deep-dive examines segment drivers, guidance, cash flow, shareholder returns, and the Medical-Surgical separation to show why the quarter strengthened the forward outlook.
McKesson Corporation (MCK) rises 7.2% after reporting earnings beats, as investors react to stronger-than-expected results and improved outlook for the healthcare distributor.
Marvell Technology, Inc. (MRVL) rises after reports of a Google custom-AI-silicon warrant deal valued at about $12.18 billion. The move reflects investor optimism about Marvell’s role in AI infrastructure, though the headline does not equal booked revenue and valuation remains elevated.